Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 15Leukemia, Lymphocytic, Chronic, B-Cell 10Lymphoma, Large B-Cell, Diffuse 8Lymphoma, Follicular 7Lymphoma, Non-Hodgkin 6Burkitt Lymphoma 6Lymphoma, Mantle-Cell 5Lymphoma, B-Cell, Marginal Zone 5Lymphoma 5Astrocytoma 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Lymphoma, T-Cell, Cutaneous 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Myelomonocytic, Acute 3Leukemia, Myeloid, Acute 3Hematologic Diseases 3Waldenstrom Macroglobulinemia 2Uveal Melanoma 2Smoldering Multiple Myeloma 2Sezary Syndrome 2Optic Nerve Glioma 2Oligodendroglioma 2Mycosis Fungoides 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large-Cell, Anaplastic 2Leukemia, Promyelocytic, Acute 2

Interventions

Vincristine 3Rituximab 3Prednisone 3Etoposide 3Doxorubicin 3Cyclophosphamide 3varlilumab 1prednylidene 1pomalidomide 1liposomal doxorubicin 1etoposide phosphate 1deltacortene 1Vorinostat 1Ultrasonography 1Nivolumab 1Lenalidomide 1Immunoglobulin G 1Endoscopy 1Electrocardiography 1Echocardiography 1Disulfides 1CT-P10 1Bronchoscopy 1Bone Marrow Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoma, Primary Effusion × Lenalidomide × Clear all
NCT02911142 2025-07-28

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
17 enrolled 21 charts
Lymphoid

Lymphoma, B-Cell, Lymphoma, AIDS-Related, Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡